产品中心您的位置:网站首页 > 产品中心 > 生物试剂 > 其他生化试剂 > 344458-19-1PJ34 344458-19-1

PJ34 344458-19-1

更新时间:2024-04-13

访问量:583

厂商性质:经销商

生产地址:上海一基

简要描述:
PJ34 344458-19-1
上海一基实业有限公司是主要从事配套试剂的生产和销售的企业,产品用途:科研实验,标准对照品研究中心代理的作为一种衡量标准

PJ34  344458-19-1

PJ-34
分子式:C17H17N3O2   分子量:295.34
 
产品描述
PJ-34是PARP抑制剂,EC50为20 nM,同等效果作用于PARP1/2。
靶点
PARP
         
IC50
20 nM (EC50)
         
体外研究
PJ34 is a potent, phenanthridinone PARS inhibitor, which is approximay 10,000 times more potent than the prototypical PARS inhibitor 3-aminobenzamide. PJ34 inhibited peroxynitrite-induced cell necrosis with EC50 of 20 nM. PJ34 provides cardioprotection by decreasing myocardial infarct size and enhancing postischemic regional and global functional recovery.
体内研究
PJ34 suppresses the development of clinical signs of EAE in MBP-immunized PLSJL mice. PJ34 exerted therapeutic effects at the onset of EAE that are associated with reduced CNS inflammation and the maintenance of neurovascular integrity. PJ34 partially inhibits the expression of TNF-α and ICAM-1 in the Spinal Cord Tissues of MBP-Immunized Mice.PJ34 provides significant, dose-dependent, anti-inflammatory effects in a variety of local inflammation models. PJ34 dose-dependently suppresses neutrophil infiltration and nitric oxide (but not KC and IL-1β) production in peritonitis. In a model of systemic endotoxemia, PJ34 pretreatment significantly reduces plasma levels of TNF-α, IL-1β and nitrite/nitrate (breakdown products of nitric oxide) production. PJ34 treatment (oral gavage) induces a significant suppression of the inflammatory response in dextran sulfate colitis, multiple low dose streptozotocin diabetes and cyclophosphamide-accelerated autoimmune diabetes in the non-obese diabetic mice, and reduces the degree of mononuclear cell infiltration into the iris in an endotoxin-induced uveitis model.
溶解性
DMSO 28 mg/mL,水 <1 mg/mL,乙醇 <1 mg/mL
稳定性
2年 -20°C粉状,6月-80°C溶于DMSO

留言框

  • 产品:

  • 您的单位:

  • 您的姓名:

  • 联系电话:

  • 常用邮箱:

  • 省份:

  • 详细地址:

  • 补充说明:

  • 验证码:

    请输入计算结果(填写阿拉伯数字),如:三加四=7